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In the United States, the number of cases of TB
disease has been falling since the beginning of
the century. The availability of highly effective
treatment accelerated this decline, and by 1970
the Advisory Council for the Elimination of
Tuberculosis (ACET) committed to the goal of
eliminating TB in the United States by the year
2010.  Elimination was defined as less than one
case per one million persons per year.  
After decades of success, the nation became
complacent and lackadaisical about TB. Monies
that had been targeted toward TB prevention
and control were diverted to other programs, and
the country witnessed a resurgence of TB.
Between 1985 and 1992, the number of TB
cases reported increased over 20%. Fueled by
both the deterioration of the public health system
and the HIV epidemic, TB cases and drug resis-
tance grew at a worrisome pace throughout the
latter part of the eighties and early nineties.
It has been estimated that it takes 100- 200 indi-
viduals living together in close contact to support
the ongoing transmission of tuberculosis (TB).
Therefore, it should not have been surprising
that when prisoners with high rates of LTBI and
HIV infection were clustered in overcrowded,
poorly ventilated congregate living environ-
ments, that the situation was perfect for cultivat-
ing TB. The first documentation of transmission
of multidrug-resistant TB (MDR-TB) in a correc-
onal system occurred in 1991, when 8 cases of
MDR-TB developed in a correctional facility in
New York. Those with active disease included
seven prisoners, all HIV-infected with CD4
counts <60, and one employee who had under-
gone radiation treatment for a malignancy and
had a CD4 count of 110. All eight individuals
died.1
Contemporaneously, an inmate in California with
MDR-TB had multiple lapses in unsupervised
therapy during which he was not housed in neg-
ative pressure respiratory isolation. A contact
investigation revealed skin test conversions
among staff.2
Subsequently during 1995-1996, staff from the
California Department of Corrections and health
services and local health departments investi-
gated two outbreaks of drug-susceptible TB. The
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Table 1: Percentage of TB Cases, by State5
Area
United States
Oklahoma
South Carolina
Arizona
Texas
Florida
Georgia
New York State
Ohio 
Louisiana
Missouri
California
Total Number of
TB cases in 2000
16,377
154
286
261
1,506
1,171
703
412
340 
331
211
3,297
% of Population
Incarcerated^
0.49
0.67
0.55
0.51
0.78
0.44
0.53
0.37
0.41
0.78
0.49
0.48
% of TB cases in
Inmates
3.6
10.4
9.1
8.0
6.3
5.8
5.3
4.9
4.4
4.3
3.8
3.5
^Calculated by dividing the number of prisoners under the jurisdiction of State or Federal authorities,
midyear 200018, by the state population, July 1, 2000.19
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outbreaks occurred in two state correction-
al institutions with dedicated HIV housing
units. In each outbreak, all cases were
linked by IS6110-based DNA fingerprinting
of MTB isolates. In all, 30 cases of TB were
diagnosed, including one case in a visitor.
The findings indicated that MTB can spread
rapidly among HIV-infected inmates and be
transmitted to their visitors and prison
employees, with secondary spread to the
community.3
And finally, demonstrating that those who
do not learn from the past are condemned
to repeat it, South Carolina experienced an
outbreak in 1999-2000 in a unit housing
HIV infected prisoners. In all, TB disease
developed in 31 prisoners and one medical
student.4
Nationwide, the rate of active TB cases in
the incarcerated is 10-20 times greater
than that in the general U.S. population.
Data from 2000 reveals an inordinate num-
ber of TB cases in residents of correctional
facilities as compared to the nation as a
whole (Table 1, p. 1).
In 2000, the Institute of Medicine (IOM)
released a report entitled Ending Neglect:
The Elimination of Tuberculosis in the
United States. This report stated "… with-
out question the major reason for the resur-
gence of tuberculosis was the deterioration
of the public health infrastructure essential
for the control of tuberculosis." The report
went on to say, "The question now con-
fronting the United States is whether anoth-
er cycle of neglect will be allowed to begin
or whether, instead, decisive action will
be taken to eliminate the disease."
Additionally, "at the current rate of decline,
… it will take more than 70 years to reach
the target for elimination of tuberculosis of
1 case … per million population." One rec-
ommendation of the IOM was to increase
targeted skin testing and treatment of LTBI
programs for high-risk groups such as
inmates of correctional facilities.6
Another area of concern is the increasing
proportion of TB cases in this country
that develop among the foreign born.
During 2000, a total of 16,377 U.S. cases
of TB were reported, representing a 39%
decrease from 1992 (26,673 cases).
However, the case rate among foreign-born
persons remains at least seven times high-
er than among U.S.-born persons. Of the
26,673 cases in 1992, 7,270 (34.2 per
100,000 population) cases were reported
among foreign-born persons, representing
27% of all cases. Of the 16,377 cases in
2000, 7,554 (25.8 per 100,000 population)
were among foreign-born persons, repre-
senting 46% of all cases (Figure 1).7
The number of states with >50% of their
annual total of reported TB cases among
foreign-born persons increased from
four in 1992 to 21 in 2000. Of these 21
states, California, Hawaii, Massachusetts,
Minnesota, and New Hampshire had >70%
of their annual total of cases among for-
eign-born persons.7
The proportion of patients with MDR-TB
decreased from 486 (3%) of 17,684 in 1993
to 141 (1%) of 12,056 in 2000.  However, of
the total number of reported MDR-TB
cases, the proportion occurring in foreign-
born persons increased from 31% in 1993
to 72% in 2000.7
Clearly, TB will not be brought under con-
trol in this country without a greater empha-
sis being placed upon the diagnosis and
treatment of LTBI among the incarcerated.
In the nation's largest correctional systems
(California, Texas, Florida, New York) for-
eign-born prisoners make up a significant
number of the total detainees. Studies have
demonstrated the prevalence of LTBI
among prisoners to be from 14% to 25%.
Other studies have shown that the longer
prisoners are incarcerated, the more likely
they are to have a positive  tuberculin skin-
test result. This data supports the probabil-
ity that transmission of TB is occurring with-
in correctional facilities. Once again, as
with HIV, hepatitis, mental illness, STDs,
and innumerable other public health issues
it becomes clear that as goes the health of
the incarcerated, so goes the health of the
nation.  
What then, is the role of this nation's cor-
rectional health care providers when it
comes to TB? Much of the information that
follows is based upon the guidelines for the
Prevention and Control of Tuberculosis in
Correctional Facilities: Recommendations
of the Advisory Council for the Elimination
of Tuberculosis, MMWR  1996 45 (RR-8).8
As with any other medical effort in the cor-
rectional setting, success of a TB infection
control program depends upon the active
cooperation of custody. The first step there-
fore is to involve each facility's sheriff or
warden in the implementation of a TB con-
t ol plan. All medical and custodial staff
must be trained about their role in this plan.  
All correctional facilities, even those in
which few TB cases are expected to occur,
should designate a person or group of per-
sons who will be responsible for the facili-
ty's TB infection-control program. These
persons should have the authority to devel-
op, implement, enforce, and evaluate TB
infection-control policies. If supervisory
responsibility is assigned to a committee,
one person should be designated as the
contact person to whom questions and
problems can be addressed. In systems
with more than one facility, one person
should be designated to oversee TB infec-
tion-control activities throughout the sys-
tem.  
TB infection-control officials and all clini-
cians who treat inmates or employees of
correctional facilities should be familiar with
current guidelines concerning TB from
the Centers for Disease Control and
Prevention, the American Thoracic Society/
CDC,9 and the National Commission on
Correctional Health Care (NCCHC).10, 11
Medical facilities located within correctional
facilities should conduct a thorough risk
assessment and follow the recommenda-
tions in the CDC Guidelines for Preventing
the Transmission of Mycobacterium tuber-
culosis in Health-Care Facilities.12 Last
month HEPP News editors participated in
the drafting of a revision to this document,
attempting to ensure that the unique chal-
lenges of correctional TB control will be
addressed. 
Correctional facility officials should form
close working relationships with their state
and local health departments, which can
assist correctional facilities in formulating,
implementing, and evaluating TB control
activities. Correctional staff should ensure
that they have access to same day chest
adiographs, induced sputum collection,
24-hour turn around time for AFB sputum
smears, and a sufficient number of nega-
tive pressure respiratory isolation rooms.
In addition, laboratories processing AFB
specimens must utilize rapid culture tech-
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Figure 1: Number of cases of TB in U.S.-born and foreign-born 
persons - United States, 1992-2000
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Dear Colleagues,
My University of Washington colleagues and I recently returned from Peru where we regular-
ly meet with our fellow Peruvian HIV Prevention Trial Unit (HPTU) and HIV Vaccine Trials Unit
(HVTU) collaborators. Like most Latin American countries, Peru is a largely impoverished
nation.  In contrast to most African countries, however, the prevalence of HIV in the general
population in Peru is still relatively low.  HIV incidence in certain high-risk groups such as gay
and bisexual men is very high providing opportunities for assessing and implementing HIV pre-
vention strategies.
Dr. De Groot described how patients in Mali suffer and die from OIs commonly treated in devel-
oped nations due to lack of access to treatment in the developing world (HEPP, January 2002);
the same is often true in Peru. Access to antiretroviral medications is also limited in Peru.
Unlike many African countries, though, the Peruvian government makes PCP and TB prophy-
laxis universally available to patients in the publicly-financed health care programs.
What stands out most in my mind is the Peruvian National Tuberculosis (TB) Control Program
implemented in 1990 - a model system more successfully implemented than those in most
developed countries.  Peru is one of the seven countries meeting the WHO target goals for
tuberculosis and has adopted "universal" Directly Observed Therapy (DOT).  Peru’s program
has resulted in a national rate of decline of >5.9% per year from 1991-2000, indicating that
70% (91,000) of possible TB-related deaths were averted.
In contrast to the largely successful Peruvian TB Control, the U.S. system has largely been a
failure, especially in controlling and treating TB among inmates and foreign born persons.
Because of these problems, we dedicate this month’s issue to TB in corrections. Dr. Bick out-
lines the TB problem and summarizes the inordinate rates of TB among inmates and foreign
born persons, providing a rational and practical approach to and summary of CDC guidelines
for control of TB in correctional institutions. We can only hope that correctional health care
providers will some day be given sufficient support to implement adequate TB control pro-
grams in our nation’s correctional institutions.
After reading this issue, health care providers should be familiar with many aspects of TB care,
including the CDC guidelines for managing tuberculosis in the correctional setting; how to
manage a positive PPD skin test; and understand the complications involved in treating a
patient who is both HIV-and TB-positive.
Dr. Stephen Tabet, MD, MPH
Letter from the Editor
4niques (i.e. bactec systems) and perform
gene probe assays on positive cultures to
ensure prompt species identification.
Access to DNA fingerprinting of positive cul-
tures is an important tool in the event of an
outbreak situation. 
The TB infection control program should be
responsible for the following three essential
TB control activities:
I. Screening: identifying persons who are
infected with M. tuberculosisor who have
active TB disease (see HEPPigram, p. 6); 
II. Containment: preventing transmission of
M. tuberculosisand adequately treating per-
sons who have latent TB infection or active
TB disease; and 
III. Assessment: monitoring and evaluating
the screening and containment activities. 
The remainder of this article will focus on
screening for and treatment of active TB and
LTBI. 
I. Screening
Screening for active TB and LTBI should
take place a) at the time of intake, b) at least
annually thereafter, and c) whenever signs
or symptoms develop that might be due to
TB disease.
a. At intake
During medical evaluation at intake (“bus
screening”), inmates should be asked if they
have had active TB disease or if they have
been treated for latent TB infection or active
TB disease. This information should be
recorded in each inmate's medical record.
Any inmate who has a history of inadequate
treatment for TB disease should undergo a
thorough medical evaluation followed by
prompt re-initiation of therapy.
All new arrivals should be evaluated for
signs or symptoms consistent with active
TB.  Those with symptoms of TB (e.g., a pro-
ductive, prolonged cough {a cough lasting
for greater than or equal to 3 weeks};
hemoptysis {coughing up blood} fever, chills,
night sweats, easy fatigue, loss of appetite,
or weight loss) should be masked and then
placed in respiratory isolation until active TB
can be ruled out. (See HEPPigram, p. 6)
All HIV-infected persons, regardless of
whether they are symptomatic or have a
positive skin test, should be screened with a
chest radiograph. TB can be difficult to diag-
nose in HIV-infected persons or other
severely immunosuppressed persons.13
The chest radiographs of severely immuno-
suppressed persons who have pulmonary
TB might not have a classical appearance;
for example, infiltrates without cavities in any
lung zone or mediastinal or hilar lym-
phadenopathy might be present. In rare situ-
ations, the chest radiograph of a severely
immunosuppressed person who has pul-
monary TB disease may appear normal.13
Skin testing
All new arrivals should undergo screening
for TB infection with the Mantoux tuberculin
skin test using 0.1 ml of 5 tuberculin units
(TU) of PPD. Those who have a document-
ed history of a positive skin-test result, a
documented history of TB disease, or a
reported history of a severe necrotic reaction
to tuberculin should be exempt from routine
tuberculin skin-test screening. Neither preg-
nancy, lactation, nor previous vaccination
with Bacillus of Calmette and Guerin (BCG)
vaccine is a contraindication for tuberculin
skin testing. 
The reaction to the Mantoux skin test should
be interpreted by an experienced worker 48-
72 hours after the injection by measuring the
area of induration (i.e., the palpable
swelling) at the injection site. The diameter
of the indurated area should be measured
across the width of the forearm. Erythema
(i.e., the redness of the skin) should not be
measured. All reactions, even those classi-
fied as negative, should be recorded in mil-
limeters of induration. 
Generally, a tuberculin skin-test reaction of
greater than or equal to 10 mm induration is
considered a positive result in inmates and
correctional-facility employees. However, an
induration of greater than or equal to 5 mm
is considered a positive result in persons in
the following groups: 
1. close contacts of a person who has infec-
tious TB  
2. persons whose chest radiographs are
suggestive of previous TB disease;
3. persons known to have HIV infection; and 
4. persons who are at risk for HIV infection,
including injecting-drug users whose HIV
status is unknown. 
Vaccination with BCG, a TB vaccine used in
many countries, can cause a reaction to the
tuberculin skin test. No reliable method can
distinguish tuberculin reactions caused by
BCG from those caused by infection with M.
tuberculosis. A diagnosis of LTBI and the
use of preventive therapy should be consid-
ered for any BCG-vaccinated prisoner who
has a tuberculin skin-test reaction of greater
than or equal to 10 mm of induration. 
Persons who have a positive skin-test result
and no symptoms suggestive of TB should
b  screened with a posterior-anterior chest
radiograph. If an inmate has a positive skin-
test result and a diagnosis of active TB dis-
ease has been excluded, the inmate should
be considered for preventive therapy (see
Section IIb on page 5).
Sputum-smear and culture examinations
should be conducted for inmates whose
chest radiographs are suggestive of active
TB disease, regardless of their skin-test
results. In some large jails, TB control offi-
cials should consider using on-site chest
radiography to screen all inmates for TB dis-
TB in Corrections...
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Table 2: Directly Observed Therapy (DOT)15
INH
RIF**
PZA
EMB
SM
Daily
5 mg/kg (300 mg)*
10 mg/kg(600 mg)*
15-30 mg/kg(2 g)*
15-25 mg/kg(2 g)*
15 mg/kg(1 g)*
DOT 2x/week
15 mg/kg (900 mg)*
10 mg/kg(600 mg)*
50-70 mg/kg(4 g)*
50 mg/kg(4 g)*
25-30 mg/kg(1 g)*
DOT 3x/week
15 mg/kg(900 mg)*
10 mg/kg(600 mg)*
50-70 mg/kg(3 g)*
25-30 mg/kg(2.5 g)*
25-30 mg/kg(1 g)*
* Maximum dose
** RIF may be used with EFV, RTV, or RTV + SQV when there are no other PIs or NNRTIs.  When
EFV is given with RIF, increase EFV dose to 800 mg/day.  For other PI and NNRTI regimens, use
RFB with dose Adjustments in Table 3.
Table 3: PI/NNRTI + RFB Dose Adjustments15
PI or NNRTI
IDV, 1000 mg q8h
NFV, 1000 mg tid or 1500 bid
APV, 1200 mg bid
EFV, 800 mg qd
NVP, 200 mg bid
RTV, standard
RTV/SQV, 400/400 mg bid
LPV/RTV, 400/100 mg bid
RFB (Rifabutin)
150 mg/day or 300 mg 2x/wk
150 mg/day or 300 mg 2x/wk
150 mg/day or 300 mg 2x/wk
450 mg/day or 600 mg 2x/wk
300 mg/day
150 mg 2-3x/wk
150 mg 2-3x/wk
150 mg qod
APV = amprenavir, DLV = delavirdine, EFV = efavirenz, EMB = ethambutol, IDV = indinavir, 
INH = isonazide, LPV = lopinavir, NVP = nevirapine, NFV = nelfinavir, PZA = pyrazinamide, 
RFB = rifabutin, RIF = rifampin, RTV = ritonavir, SM = streptomycin, SQV = saquinavir
5ease. Such screening is particularly impor-
tant for jails in which a) the prevalence of TB
disease is high, b) the inmate population
changes rapidly, and c) the prevalence of
HIV infection and illicit-drug injection is high.
Jail officials should consult the local TB con-
trol officer for assistance in assessing the
need for, and cost-effectiveness of, such
screening. 
b. Annual follow-up screening
Inmates who had a negative skin-test result
at intake should have an annual PPD skin
test. Those who have a history of a positive
skin-test result and who have not completed
a course of preventive therapy should be
screened for symptoms of TB disease.
Annual chest radiographs are unnecessary
for the follow-up evaluation of infected per-
sons. 
c. At any time when symptoms are
detected
Inmates who at any time have symptoms
suggestive of TB disease should immediate-
ly receive a thorough medical evaluation,
including a tuberculin skin test, a chest radi-
ograph, and, if indicated, sputum examina-
tions. While under investigation, suspect
cases should be housed in a negative pres-
sure respiratory isolation room.
IIa. Containment: treat-
ment of active disease 
For most inmate-patients, the preferred ini-
tial treatment regimen includes four drugs:
isoniazid, rifampin, pyrazinamide, and either
ethambutol or streptomycin (for dosing see
Table 2; for recommended regimens, see
HIV101). Because pyrazinamide and strep-
tomycin should not be used to treat pregnant
women, pregnancy must be excluded in
women of child-bearing ages before treat-
ment for TB disease is initiated.
Furthermore, TB infected patients who are
also HIV- positive AND are on a HAART reg-
imen containing a PI or NNRTI should
receive rifabutin (RFB) instead of rifampin
(RIF) and may also require dose adjust-
ments in their HIV medications (Table 3).
Patients with sputum smear positive TB
should remain in negative pressure respira-
tory isolation until they have satisfied all of
the following conditions:
1) they have received 7-10 days of directly
observed therapy (DOT) 
2) three separate consecutive sputum spec-
imens are smear negative for AFB 
3) the patient's symptoms have improved 
Failure to respond to treatment usually is
caused by patient non-adherence to therapy,
but can also be caused by a drug-resistant
strain of MTB. Drug-susceptibility testing
should be performed on all initial MTB iso-
lates, regardless of sputum-smear results. If
an inmate is to be released or transferred out
of the facility before completing therapy, the
public health department or receiving correc-
tional facility should be notified as far in
advance as possible and should be provided
with appropriate medical records to ensure
continued adherence to and timely comple-
tion of therapy. 
All inmates being treated for active TB dis-
ease should be on DOT to ensure adher-
ence to therapy. Inadequate or interrupted
treatment for TB can result in relapse,
continued transmission, and the develop-
ment of drug-resistant disease. Therefore,
after effective therapy has begun, continued
treatment without interruption is critical until
patients complete an entire course of
therapy. 
IIb. Containment: preven-
tive therapy for LTBI
The recommended regimen for preventive
therapy in inmates, because they are at high
ri k for TB, regardless of HIV status is a sin-
gle daily dose of 300 mg of isoniazid for 9
months given by DOT. For those who are
known to be HIV sero-negative, a six month
course of therapy may be acceptable. If
daily-supervised therapy is not feasible,
twice-weekly supervised therapy with isoni-
azid (15 mg/kg of isoniazid per dose, with a
maximum dose of 900 mg) is a suitable alter-
native (see HIV101). Before release or
transfer of an inmate, provisions should be
made for the public health department or
receiving facility to oversee completion of an
appropriate course of preventive therapy.
During the entire treatment period, persons
receiving preventive therapy should be mon-
itored monthly by medical personnel for
signs and symptoms of adverse reactions.
Because of the high rate of underlying liver
disease in inmates, baseline transaminase
measurements should be obtained at the ini-
tiation of preventive therapy.  Those who are
found to have abnormal baseline transami-
nases and those who have other factors
associated with an increased risk for hepati-
tis (chronic liver disease, daily use of alco-
hol, injecting- drug use, or current use of
another medication that might cause interac-
tions) should have transaminases measured
monthly during the course of treatment. 
An alternative short course treatment regi-
men for LTBI utilizing 2 months of rifampin
and PZA was found to be safe and highly
effective in HIV-infected individuals with
LTBI. Subsequently, however, fatal and
severe liver injuries have been associated
with the use of this regimen in HIV sero-neg-
ative individuals.16, 17It is not clear why those
who are HIV sero-negative would be more
likely to develop side effects from this regi-
men than those who are HIV sero-positive.
However, it seems prudent to advise that
the 2-month RIF-PZA treatment regimen for
LTBI should be used with caution, especially
in patients concurrently taking other medica-
t ons associated with liver injury, and those
with alcoholism, even if alcohol use is dis-
continued during treatment. RIF-PZA is not
r commended for persons with underlying
liver disease or for those who have had INH-
associated liver injury. For persons not
infected with HIV, 9 months of daily INH
remains the preferred treatment for LTBI; 4
months of daily RIF is an acceptable alter-
native. 
Persons for whom TB preventive therapy is
r commended but who refuse or are unable
to complete a recommended course of ther-
apy should be counseled to seek prompt
medical attention if they develop signs or
symptoms suggestive of TB. Routine, peri-
odic chest radiographs of persons who have
a documented history of a positive skin-test
result usually are not useful for detecting dis-
ease in the absence of symptoms.
Conclusion
After decades of decline in this country, TB
cases rose during the latter part of the eight-
ies. This resurgence was fueled by both the
HIV epidemic and the deterioration of the
public health infrastructure.  With renewed
attention and increased resources, TB cases
a e again beginning to decline. An increas-
ingly disproportionate number of new cases
are diagnosed among those who are foreign
b rn and among the incarcerated. MDR-TB
cases are also more common in these two
populations. Elimination of TB in this country
will require intensified screening, treatment,
and containment efforts among prisoners
and the foreign born. Those of us working in
correctional health are on the front line of
this effort to rid our nation of TB. Success will
require education of all correctional employ-
ees and close cooperation with custody staff
as well as state and local health depart-
ments. 
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HEPPigram: Management of a Positive PPD Skin Test
The following is one approach to the incarcerated patient with a newly positive PPD skin test* on routine screening, regard-
less of HIV status. This algorithm represents an aggressive approach, appropriate for the correctional setting because of:  
1) congregate living environments, which facilitate the rapid spread of MTB;
2) the high prevalence of HIV, much of which is undiagnosed.
*Positive PPD Skin Test is:
–  >5mm for HIV + patient.
–  >10mm for HIV- patient.
–  an increase of >5mm from a prior PPD skin test.
–  >5mm if patient has a history of TB contact.
**Symptoms include hemoptysis, cough, fever, weight loss, and night sweats.
***Classically, MTB presents with apical infiltrates. In those with HIV infection, the chest x-ray may be normal, or reveal mediastinal
adenopathy, or middle/lower lobe infiltrates.
^If same day chest x-ray is not available, immediately isolate patient in negative pressure setting, use masking when out of negative
pressure room. Obtain chest x-ray as soon as possible.
Symptomatic**
Conduct symptom interview
Immediately mask patient and obtain same day chest x-ray.^
Normal chest x-ray.
Isolate patient.  
Send 3 sputum for AFB smear
and culture. Evaluate for other
causes of symptoms. 
If smears are negative, 
prophylax for latent 
TB infection.
Prophylax for latent 
TB infection.
Normal chest x-ray.Newly abnormal *** chest x-ray consistent
with MTB, or abnormal chest x-ray 
consistent with MTB and no old films 
to compare.
Isolate patient. 
Send 3 sputum for AFB smear and 
culture. Evaluate for and treat other 
etiologies. Begin 4 drug 
antitubercular regimen while 
awaiting sputum results.
Obtain chest x-ray.
Asymptomatic
7Tuberculosis Treatment and Prophylaxis Recommendations
1. INH/RIF/PZA/EMB (or SM) daily x 2
months
2. INH/RIF/PZA/EMB (or SM) daily x 2
weeks, then 2-3x/week x 6 weeks
3. INH/RIF/PZA/EMB (or SM) 3x/week x
8 weeks
1. INH/RFB/PZA/EMB daily x 8 weeks
2. INH/RFB/PZA/EMB daily x 2 weeks,
then 2x/week x 6 weeks
1. INH/SM/PZA/EMB daily x 8 weeks
2. INH/SM/PZA/EMB daily x 2 weeks,
then 2-3x/week x 6 weeks
Induction Maintenance
Rifampin (RIF)-based therapy (no concurrent use of PIs or NNRTIs)
Comment
INH/RIF daily or 2-3x/week x 18 weeks
INH/RIF or 2-3x/week x 18 weeks
INH/RIF/PZA/EMB (or SM) 3x/week x 4
months
INH/RFB daily or 2x/week x 18 weeks
INH/RFB daily or 2-3x/week x 18 weeks
INH/SM/PZA 2-3x/week x 30 weeks
INH/SM/PZA 2-3x/week x 30 weeks
RIF-containing regimens preclude con-
current PIs or NNRTIs except with EFV,
RTV, and RTV + SQV. Assess HIV at 3
month intervals to determine needs for
ART. A 2-week wash-out period is
required between the last RIF dose and
initiation of PI or NNRTIs.
Monitor for RFB toxicity-arthralgias,
uveitis, leukopenia. Dose modifications
of RFB and PIs/NNRTI when given con-
currently (see Table 3, p. 4). RFB
should not be given with SQV or DLV.
SM is contraindicated in pregnant
women as is PZA. If SM cannot be con-
tinued for 9 months add EMB and treat-
ment should be extended to 12 months.
Preferred 
– INH 300 mg/day + pyridoxine 50
mg/day, x 9 mo or up to 12 mo w/ 
interruptions (AII)
– INH 900 mg + pyridoxine 100 mg
2x/wk DOT, x 9 mo or up to 12 mo w/
interruptions (BII) 
patient not receiving PI or NNRTI:
– **RIF 600 mg/day + PZA 20
mg/kg/day, x 2 mo or up to 
3 mo w/ interruptions (AI) 
(**see NOTE below)
Alternatives*
– RIF 600 mg/day x 4 mo (BII)
* patients receiving PI or NNRTI need
RFB 15-30 mg/kg/day in place of
(RIF)/PZA and antiretroviral dose
adjustment if receiving PI or NNRTI
(BIII) (see dose adjustments in Table 3
in the main article) x 2 mo
Special Cases
INH-resistant strain:RIF 600 mg/day +
PZA 20 mg/kg/day x 2 mo (AI); alterna-
tive: RIF 300 mg/day PO x 4 mo (CIII)
INH- and RIF- resistant strain:use 2
agents with anticipated activity-
EMB/PZA or levofloxacin/PZA 
Pregnancy: INH regimens
Monitoring:baseline LFTs (bilirubin,
AST & ALT), and CBC if treated w/ RIF
or RFB- CBC.  Repeat tests if baseline
tests are abnormal or if there are symp-
toms of hepatitis.  Recipients of INH or
RIF alone: clinical review monthly; RIF
or RFB + PZA: review at 2,4, and 8 wks
For dosing, see Table 2 in the main article. 
* Treatment of bone or CNS disease should be at least 1 year.
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Rifabutin (RFB)-based therapy (concurrent PI or NNRTI)
Streptomycin (SM)-based therapy (concurrent PI or NNRTI)
Table A: TREATMENT of ACTIVE TB*
Table B: PROPHYLAXIS of LATENT TB INFECTION
Risk: PPD+ (>5 mm induration) without prior prophylaxis or treatment (AI), recent TB contact (AII), or history of inadequately
treated TB that healed (AII) (MMWR 2000; 49: [RR-6] and MMWR 1998; 47 [RR-20]).
** NOTE:The 2-month RIF/PZA treatment for latent tuberculosis infection (LTBI) has been shown to cause liver injury in HIV-
negative patients. Therefore, in most cases, the 9-month INH regimen is preferred for treatment of LTBI.  The RIF/PZA regi-
men should be used with caution especially in those patients concurrently taking other medications associated with liver injury,
and those with alcoholism, even when alcohol use is discontinued during treatment.  Full information on recommendations
concerning RIF/PZA are available in the MMWR 50 (34): 733-735 or at http://www.cdc.gov/mmwr/PDF/wk/mm5034.pdf
WARNING: Six (6) months of TB treatment may not be sufficient for HIV-positive patients (see Inside News, p. 8).
EMB = ethambutol, INH = isoniazid, PZA = pyrazinamide, RFB = rifabutin, RIF = rifampin, SM= streptomycin
Adapted from: Bartlett JG, Gallant JE.  Medical Management of HIV Infection 2001-2002 Edition.  Johns Hopkins University, 
Baltimore MD 2001 (112-113).
International Conference on
Emerging Infectious Diseases
March 24-27, 2002
Atlanta, Georgia
Fee: $350
Visit: http://www.cdc.gov/iceid/
Call: C. Schable, 404.639.4581
Email: cas1@cdc.gov
HIV Pathogenesis,
Antiretrovirals, and Other
Selected Issues in HIV Disease
Management
March 25, 2002
New York, NY
Sponsored by the International
AIDS Society-USA
Fee: $55
Visit: http://www.iausa.org
Call: 415.561.6725
Email: cme@iausa.org
Clinical Updates in 
Correctional Health Care
April 13-16, 2002
Fort Lauderdale, Florida
Fee: $225 Academy members,
$300 non-Academy members
Visit: www.ncchc.org
Fax: 773.880.2424
Twelfth Annual Clinical Care
Options for HIV Symposium
April 25-28, 2002
Miami, Florida
Sponsored by the Northwestern
University School of Medicine
Register by March 25, 2002
Visit: http://imedoptions.com
Call: 888.391.3996
Sixth Annual HIV Update:
Contemporary Issues in
Management
June 6-8, 2002
Boston, Massachusetts
Fee: Before April 26: $550, 
$350 Residents and Fellows; 
after April 26: $595, 
$375 Residents and Fellows
Call: 617.384.8600
Fax: 617.284.8686
Email: hms-cme@hms.harvard.edu
XIV International AIDS
Conference
July 7-12, 2002
Barcelona, Spain
Fee: before May 1 2002: $950;
after May 1 2002: $1050 (special
rates and scholarships available)
Visit: www.aids2002.com
Email: aids2002.registration@
congrex.se
Save the 
Dates
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Tuberculosis: the Situation in the United
States, 2000
MMWR 2/8/02 51(5):101-04;
http://www.cdc.gov/mmwr/PDF/wk/mm5105.pdf
As reported in the MMWR, the CDC announced
a 7% drop in the number of TB cases in the
United States from 1999-2000 (June 2001).  The
data indicate a drop in TB cases among US-born
populations combined with a rise in the number
of cases among foreign-born US populations
(see Main Article).
Six-Month TB Treatment May Not Be Effective
for HIV-Positive Patients
Clin Infect Dis 2001;33:1762-1769
A retrospective study of patients infected with
drug susceptible tuberculosis (TB) has found
that the 6-month TB treatment usually given in
the United States may not provide protection
against TB recurrence or relapse for HIV-positive
patients. HIV-positive patients were more likely
to have a recurrence of TB than were HIV-nega-
tive patients (2.4% v. 0.6%); the same was true
for the risk of TB relapse (3% v.0.8%).  Clinicians
should be aware that there is a possibility of TB
recurrence or relapse 6 to 9 months after a
patient begins treatment, and that this risk is far
greater for HIV-positive patients. It is recom-
mended that the sputum of HIV-positive patients
be checked 3 months after the short course (6
month) TB treatment for assessment.
California Settles Lawsuit Involving Prison
Health Care
Reuters, 1/30/02
A class-action lawsuit brought against the
California Department of Corrections (Calif.
DOC) cited "cruel and unusual punishment,"
alleging that the Calif. DOC did not provide ade-
quate healthcare to its 160,000 inmates.The suit
alleged that the Calif. DOC was "lax" in assess-
ing the medical needs of its inmates in part
because it did not hire enough medical person-
nel, did not have adequate screening procedures
for incoming inmates, delayed testing and treat-
ment, and was unable to deal with chronic ill-
nesses, including HIV and diabetes. The Calif.
DOC has settled this lawsuit, agreeing to
improve health care over the next several years
and allowing an independent firm audit and mon-
itor the state's progress.
HIV
Simplified Efavirenz Regimen Approved
FDA Release, 2/4/02
The FDA has approved a once-daily, single pill
formulation of the NNRTI efavirenz (brand name
Sustiva).  The new once-daily pill is a 600 mg
tablet that can be taken in place of the three 200
mg capsules currently available.  The new
dosage should be available by the end of
February; the old formulation of 200 mg cap-
sules will continue to be available as well.
Decreased pill burdens may increase patient
adherence. 
FDA Approves Combining Amprenavir +
Ritonavir 
FDA Release, 2/5/02
The FDA has approved new dosing for the con-
comitant use of Amprenavir (brand name
Agenerase) and Ritonavir (brand name Norvir).
The new package insert of amprenavir now
includes the following dosing options when used
in conjunction with ritonavir: 1200 mg ampre-
navir plus 200 mg ritonavir once daily or 600 mg
amprenavir plus 100 mg ritonavir twice daily.
The new information on these medications used
concomitantly is available from the FDA at
http://www.fda.gov/cder/foi/label/2002/21007s01
0lbl.pdf.
Florida: HAART No Longer Available Upon
Discharge
South Florida Sun-Sentinel, 2/13/02
HIV-positive jail inmates in Broward County,
Florida, will no longer receive a temporary (30-
day) supply of antiretroviral medications upon
release.  The supply was meant as a "stop-gap"
to give HIV-positive inmates time access med-
ication once they left the jail.  However, the new
medical services at the jail realized that the jail
did not have the proper licensure to distribute
drugs outside of the jail. Experts are concerned
that this will negatively impact the health of coun-
ty inmates released to the community. Editor’s
note: The Fla. DOC is still continuing its program
of a 30-day supply of HAART medications in
combination with its "Coordination to Care."  The
change in Broward County will not affect Fla.
DOC inmates.
Job Opening
The Washington State Dept. of Corrections is
looking for a new Medical Director. For more
information, visit http://www.wa.gov/doc/Content/
docjobs.htm, or call 360.753.1573.
Inside News
Resources & Websites
WHO Global Tuberculosis Program
www.fda.gov/cder/foi/label/2002/21007s010lbl.pdf
CDC Core Curriculum on TB
www.cdc.gov/nchstp/tb/pubs/corecurr/default.htm
Order free paper copy at https://www2.cdc.gov/
nchstp_od/PIWeb/TBorderform.asp
CDC Division of Tuberculosis Elimination
www.cdc.gov/nchstp/tb/
OSHA Tuberculosis Site
www.osha-slc.gov/SLTC/tuberculosis/
Report from the 39th Annual IDSA: 
Tuberculosis Update
www.hopkins-tb.org/events/idsa39.shtml
NEW Adult and Adolescent HIV Treatment
guidelines
www.hivatis.org/guidelines/adult/Feb04_02/
AdultGdl.pdf
NEW HHS Guidelines for the use of
Antiretrovirals in Pregnant Women
www.hivatis.org/guidelines/perinatal/Feb4_02/
Perin.pdf
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Self-Assessment Test for Continuing Medical Education Credit
Brown Medical School designates this educational activity for 1 hour in category 1 credit toward the AMA Physician’s Recognition Award.
To be eligible for CME credit, answer the questions below by circling the letter next to the correct answer to each of the questions. 
A minimum of 70% of the questions must be answered correctly. This activity is eligible for CME credit through October 30, 2002. 
The estimated time for completion of this activity is one hour and there is no fee for participation.
1. What is considered to be a positive PPD skin test for an HIV-
negative incarcerated patient?
a) >5 mm
b) >5 mm if the patient has a history of TB contact
c) >5 mm increase from a prior PPD skin test
d) >10 mm
e) b, c, or d
2. It is recommended that screening for TB in correctional facilities
occurs:
a) At intake, and prior to release
b) At intake, annually thereafter, and when signs/symptoms 
develop that may be due to TB disease
c) At intake, annually thereafter, and prior to release
d) At intake and annually thereafter, only for patients who have 
sentences of more than 12 months
e) On an annual basis and prior to release
3. Patients with sputum smear positive TB should remain in nega-
tive pressure respiratory isolation until they satisfied which of the
following conditions?
a) Two consecutive sputum smears are negative for AFB
b) The patient's symptoms have improved
c) Three consecutive sputum smears are negative for AFB
d) The patient has received 7-10 days of directly observed 
therapy (DOT)
e) a, b, and d
f) b, c, and d
4. Which of the following statement(s) is (are) TRUE?
a) There have been multiple documented transmissions of 
multi-drug resistant TB (MDR-TB) in correctional settings.
b) There has been a steady decline in the tuberculosis case 
rate in the United States since the 1980's
c) The IOM report cited  that the deterioration of public health 
infrastructure was to blame for the resurgence of tuberculosis
d) The rate of active TB cases nationwide is 10-20 times 
higher in the incarcerated than the general US population
e) a, b, and c
f) a, c, and d
5. When a patient is on nelfinavir (NFV, Viracept) as part of a
HAART regimen, what is the proper dose of rifabutin (RFB) to use
concurrently for treating TB?
a) 150 mg/ day
b) 300 mg/ day
c) 450 mg/day
d) 600 mg/day
e) 300 mg/wk
6. Neither pregnancy, lactation, nor previous vaccination with BCG
are contraindications for tuberculin skin testing.
a) True
b) False
BROWN MEDICAL SCHOOL •  OFFICE OF CONTINUING MEDICAL EDUCATION •  BOX G-A2  •  PROVIDENCE, RI 02912
The Brown Medical School is accredited by the Accreditation Council for Continuing Medical Education (ACCME)to provide continuing medical 
education activities for physicians.  
The use of the Brown Medical School name implies review of the educational format and material only.  The opinions, recommendations 
and editorial positions expressed by those whose input is included in this bulletin are their own.  They do not represent or speak for the 
Brown Medical School.
For Continuing Medical Education credit please complete the following and mail or fax to 401.863.2660 or 
register online at www.hivcorrections.org. Be sure to print clearly so that we have the correct information for you.
Name __________________________________________________________________ Degree ____________________
Address ____________________________________________________________________________________________
____________________________________________________________________________________________________
City ____________________________________________________ State ________ Zip ________________________
Telephone ________________________________________________ Fax ______________________________________
HEPP News Evaluation
5 Excellent    4 Very Good    3 Fair    2 Poor    1 Very Poor
1. Please evaluate the following sections with respect to:
educational value clarity
Main Article 5  4  3  2  1   5  4  3  2  1     
HEPPigram 5  4  3  2  1   5  4  3  2  1  
HIV 101 5  4  3  2  1   5  4  3  2  1
Save the
Dates 5  4  3  2  1   5  4  3  2  1
2. Do you feel that HEPP News helps you in your work?
Why or why not?
3. What future topics should HEPP News address?
4. How can HEPPNews be made more useful to you?
5. Do you have specific comments on this issue?
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